Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel peptidomimetic hematoregulatory compounds.

D A Heerding1, M Abruzzese, D Alberts

  • 1Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426, USA. dirk_a_heerding@sbphrd.com

Bioorganic & Medicinal Chemistry Letters
|March 31, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-genome sequencing reveals genomic diversity and selection signatures for adaptation in South African Afrikaner and Bonsmara cattle.

Frontiers in genetics·2026
Same author

Sterile granulomatous panuveitis in dogs in the United Kingdom: A review of 33 cases.

Veterinary ophthalmology·2024
Same author

The Peripheral Neuropathy Prevalence and Characteristics Are Comparable in People with Obesity and Long-Duration Type 1 Diabetes.

Advances in therapy·2022
Same author

Association between osteoarthritis-related serum biochemical markers over 11 years and knee MRI-based imaging biomarkers in middle-aged adults.

Osteoarthritis and cartilage·2022
Same author

Assessing the carbon capture potential of a reforestation project.

Scientific reports·2021
Same author

Mirogabalin besylate in the treatment of neuropathic pain.

Drugs of today (Barcelona, Spain : 1998)·2020

Novel peptidomimetic compounds stimulate hematopoietic synergistic factor (HSF) to enhance host defense. These agents show potential for therapeutic hematoregulation.

Area of Science:

  • Pharmacology
  • Immunology
  • Medicinal Chemistry

Background:

  • Hematoregulatory compounds are crucial for modulating host defense mechanisms.
  • Understanding structure-activity relationships (SAR) of peptides like SK&F 107647 (1) is key to developing new therapeutic agents.
  • Peptidomimetics offer a promising avenue for drug design due to their stability and bioavailability.

Purpose of the Study:

  • To report the activity of a novel series of peptidomimetic hematoregulatory compounds.
  • To investigate compounds designed using a pharmacophore model derived from SK&F 107647 (1) SAR.
  • To explore the potential of these compounds as novel therapeutic agents.

Main Methods:

  • Design of peptidomimetic compounds based on a pharmacophore model.

Related Experiment Videos

  • Evaluation of the hematoregulatory activity of the novel compounds.
  • Assessment of the compounds' ability to induce hematopoietic synergistic factor (HSF).

    • Main Results:

    • The novel peptidomimetic compounds demonstrated significant hematoregulatory activity.
    • These compounds were found to induce hematopoietic synergistic factor (HSF).
    • The induced HSF was observed to modulate host defense.

    Conclusions:

    • The novel series of peptidomimetic compounds exhibit promising hematoregulatory properties.
    • These compounds function by inducing hematopoietic synergistic factor (HSF).
    • The findings suggest potential therapeutic applications in hematoregulation and host defense modulation.